The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) and The University of Notre Dame announced the inaugural Catalyst Advocacy Scholars Summit (CASS), a week-long immersive program for 12 students enrolled in Notre Dame’s Patient Advocacy Minor.
The summit runs January 5–9, 2026 in Coral Gables, Fla., and is designed to educate students on patient advocacy and biopharmaceutical operations while giving Catalyst access to student perspectives on its programs. Catalyst said it aims to attract talent to the industry and increase patient focus across scientific degree programs.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CPRX declined 1.51%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CPRX was down 0.81%, while close peers like FOLD, CGON, TVTX, and CELC showed modest gains between 0.18% and
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Conference participation | Positive | +2.4% | Announced presentation at J.P. Morgan Healthcare Conference with webcast access. |
| Nov 24 | Conference participation | Positive | +1.0% | Management participation in Bank of America CNS Therapeutics Virtual Conference. |
| Nov 19 | Growth recognition | Positive | -0.7% | Ranked on Deloitte Technology Fast 500™ based on 249% revenue growth. |
| Nov 18 | Conference participation | Positive | +0.4% | Planned presentation at Citi’s 2025 Global Healthcare Conference with webcast. |
| Nov 05 | Earnings and update | Positive | +0.2% | Reported Q3 2025 revenue growth, raised guidance, and announced share repurchase. |
Recent news, mainly conferences and strong earnings, has usually led to small positive price moves, with one modest decline on an award recognition headline.
Over the last few months, Catalyst reported strong Q3 2025 financials with total revenue of $148.4M and raised full‑year guidance to $565M–$585M, alongside a $200M share repurchase authorization and a patent trial set for March 2026. The company has maintained visibility through multiple investor conferences in November–December 2025 and was ranked #304 on the 2025 Deloitte Technology Fast 500™ with 249% revenue growth from 2021–2024. Today’s educational partnership announcement fits into this broader narrative of commercial momentum and corporate positioning rather than a clear financial catalyst.
Market Pulse Summary
This announcement highlights an educational collaboration between Catalyst and the University of Notre Dame, launching a week‑long summit for 12 students focused on rare‑disease drug development and patient advocacy from January 5–9, 2026. It reinforces Catalyst’s positioning as a commercial-stage biopharmaceutical company active in rare diseases, complementing recent conference participation and strong revenue growth. Investors may watch how such outreach supports talent development, corporate reputation, and long‑term engagement with the rare‑disease community alongside existing financial and regulatory milestones.
Key Terms
biopharmaceutical medical
AI-generated analysis. Not financial advice.
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive
CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced their inaugural Catalyst Advocacy Scholars Summit (CASS). This one-of-a-kind program was created with The University of Notre Dame’s Patient Advocacy Minor Department to provide participating students with an immersive learning experience exploring the opportunities and challenges of delivering medicine to people living with rare diseases.
“We at Catalyst are excited about this unique program that we hope will help attract the best minds to the biopharmaceutical industry and increase patient focus across scientific degree programs,” said Rich Daly, President and CEO, Catalyst. “We look forward to welcoming 12 inspiring students selected by the university to spend time with Catalyst colleagues to get to know the people and functions that make our organization successful. In addition to the students learning about the incredible work involved in Patient Advocacy and navigating the biopharmaceutical industry, Catalyst will benefit from their fresh perspective on our current programs.”
The inaugural Catalyst Advocacy Scholars Summit will be held January 5 – 9, 2026, in Coral Gables, Fla.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull (858) 717-2310 david.schull@russopartnersllc.com
FAQ
What is the Catalyst Advocacy Scholars Summit (CASS) announced on January 5, 2026 by Catalyst (CPRX)?
When and where will the inaugural CASS for Catalyst Pharmaceuticals (CPRX) take place?
How many students from Notre Dame will participate in the CPRX Catalyst Advocacy Scholars Summit?
How might the CASS program affect Catalyst Pharmaceuticals (CPRX) as a company?
Who is organizing the Catalyst Advocacy Scholars Summit with Catalyst Pharmaceuticals (CPRX)?
Will the CASS program include interactions with Catalyst Pharmaceuticals (CPRX) employees?
